South Korean drugmakers face October valuation test as approvals, trials and deals converge
AI Summary- AriBio will release global Phase 3 results for its Alzheimer's candidate AR1001 in October.
- Fosun Pharma paid $60 million for an option requiring another $80 million upon exercise.
- FDA imposed a partial clinical hold on SK Biopharmaceuticals' opacalim after animal toxicity findings.